Next-generation vascular closure device: from design transfer to repeatable, scalable commercial production

Ensera partnered with a European medical device innovator to accelerate the U.S. launch of a next-generation, single-use vascular closure device for minimally invasive surgical procedures.

By integrating Design for Manufacture (DfM) expertise with complex assembly capabilities, global supply chain coordination, and FDA‑registered manufacturing, Ensera successfully transitioned the device from design transfer to validated, scalable production, packing and sterilization management with manufacturing and validation activities aligned to FDA pre‑market authorization requirements. The result: accelerated commercialization, reliable high‑volume output and stable supply chain with enhanced clinical performance at the point of care.

The challenge

With a newly developed next-generation vascular closure device ready for commercialization, the customer faced a critical inflection point: selecting a manufacturing partner capable of translating advanced design into scalable, repeatable production.

Destined for use in minimally invasive interventional cardiology and radiology procedures, in addition to endovascular interventions, the device demanded exceptional precision, sterility assurance, and mechanical reliability. Viable and repeatable production at scale would require high accuracy tolerance injection molding, precision component integration, complex multi-step assembly, validated sterile barrier packaging, and tightly controlled manufacturing processes.

Beyond manufacturing and technical execution, the customer needed specialist Design for Manufacture (DfM) expertise, support with the required documentation for smooth regulatory clearance, and multi‑vendor global supply chain coordination.

In short: the customer required more than a contract manufacturer; they needed a strategic partner capable of aligning engineering, quality, supply chain, and regulatory disciplines to enable reliable market entry at speed.

The solution

Building on a long-standing design-through-manufacture partnership, we developed a scalable, FDA‑compliant manufacturing platform designed to support U.S. FDA pre‑market authorization and commercial launch, transitioning the device from design transfer to commercial production within the targeted timeframe.

Our customized end-to-end approach was built around the customer’s unique needs and commercial objectives, aligning several stages within a single, controlled production framework. By combining manufacturability optimization, precision assembly capability, and global supply chain alignment, with integrated sterile barrier packing and sterilization management, we significantly reduced scale-up risk, strengthened regulatory readiness, and provided a clear pathway from design transfer to robust, repeatable and scalable commercialization.

The execution

The vascular closure device program was executed through coordinated cross-functional collaboration across engineering, quality, supply chain, and operations, structured to support the customer’s forecasted commercial volumes. It included:

Engineering transfer, injection molding and assembly optimization: process development using structured DfM/DfA, tolerance analysis, early builds, and refinement of multi-step assembly processes for the device. This included alignment of molded plastic components, integration of metal elements through insert molding or controlled secondary bonding where required, and definition of repeatable manual assembly steps, supported by Manual Process Verification (MPV) to confirm process robustness and reliability prior to commercial scale-up.
Tooling and fixture development: tooling and fixture design, qualification, and integration of custom jigs and fixtures to control critical alignments and ensure repeatable, operator-independent assembly.
Supplier qualification and management: onboarding and alignment of global supply partners through technical reviews, quality agreements requirements, traceability controls, and continuity planning to support mid-volume commercial demand.

Packaging and sterilization validation: development and validation of sterile barrier blister packaging systems for the device, including semi‑customized blister formats to support device protection, handling, and clinical use; coordination of sterilization qualification including single-dose mapping and minimal dose verification, and alignment of packaging validation activities to prevent downstream bottlenecks.
Process validation and regulatory readiness: execution of OQ and PQ protocols aligned to the introduction of next-generation device components, including validation of cleaning, sealing, manual assembly (via MPV), sterile barrier packaging, and sterilization processes. This included DMR/DHR development, traceability controls, and audit preparedness to support compliant commercial release.
Commercial production readiness: cleanroom-controlled assembly, packing and kitting; validated assembly sequencing across multiple components and sub‑assemblies; semi-customized sterile barrier blister packaging; IFU and final secondary packaging; coordinated sterilization management; and compliant release of finished sterile goods for commercial distribution.

Sterile assembly and end-of-line packaging activities were performed within ISO class 7 and ISO class 8 cleanroom environments under an ISO 13485-certified quality management system, ensuring regulatory compliance and consistent product integrity.

Ensera has been a trusted partner in the evolution of our next generation vascular closure device. They enabled us to move from design transfer to FDA-ready, scalable production with confidence and pace. Their ability to translate complex design intent into validated manufacturing, while aligning with FDA premarket authorization requirements, was critical to supporting our U.S. market entry. From DfM insight and precision assembly through sterile barrier packaging, sterilization management, and supply chain coordination, Ensera delivered a robust, compliant manufacturing platform that allowed us to scale reliably and at speed.

- Chief Operating Officer, Medical Device OEM 

Impact

Our tailored, design-through-manufacture process enabled the customer to take their vascular closure device from design transfer to seamless and scalable commercial launch:

Established a validated, scalable manufacturing platform for a high-precision, single-use medical device supporting commercial market volume forecasts.
Accelerated time to market through assembly optimization, concurrent validation planning, coordinated global supply chain execution, and dedicated cross-functional program management.
Reduced manufacturing and scale-up risk by implementing robust, repeatable, cost-optimized/ commercially viable assembly processes.
Simplified operational complexity by integrating component sourcing and molding alignment, precision assembly, sterile barrier packaging, and sterilization management under one roof.
Strengthened regulatory confidence through production in FDA-inspected facilities with validated processes and full documentation readiness.
Supported FDA pre‑market authorization through validated manufacturing, packaging, sterilization, and documentation readiness aligned to U.S. regulatory submission requirements.

Considering a technical transfer?

Speak with our team about technical transfer across the product lifecycle, from NPI and next‑generation devices through to legacy products, accelerating timelines while managing operational complexity.

Enquire now